Gene therapy safety check: 400 cancer patients monitored for years
NCT ID NCT06885424
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for delayed side effects and see how long any benefits last. The goal is to better understand the safety and durability of this gene therapy approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Banner Health
Gilbert, Arizona, 85234, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NYU Langone Medical Center
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could a vaccine help fight Hard-to-Treat cancers?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Blood and gut clues may flag pancreatic cancer risk early